SNRI antidepressants and psilocybin.
5 records in this group. 3 have published human data with psilocybin or another classic psychedelic; the rest draw on each medication's own pharmacology and label. State rules are summarized for Colorado, Oregon and New Mexico.
Overview
Reviewed 2026-10-18SNRIs block reuptake of serotonin and noradrenaline (norepinephrine). In an online survey, reports from people taking SSRIs or SNRIs described weaker-than-expected psilocybin effects more often than reports from people taking bupropion, which does not act directly on serotonin (47–55% vs 29%; Gukasyan 2023).
Stopping an SNRI, especially suddenly, can cause withdrawal (discontinuation) symptoms (Effexor XR prescribing information). In one case report, a person who stopped duloxetine before a second psilocybin session had moderate discontinuation symptoms (Do 2024). The psilocybin trial that continued antidepressant treatment enrolled people taking SSRIs, not SNRIs (Goodwin 2023).
Their noradrenaline action can raise blood pressure and heart rate; venlafaxine's label describes dose-related increases in blood pressure (Effexor XR prescribing information). Psilocybin has been shown to raise heart rate and blood pressure in some healthy adults (Becker 2022), so the effects may add together. In the same case report, psilocybin 25 mg taken during duloxetine plus vortioxetine was followed by headache and a blood pressure rise from 119/77 to 141/93 mm Hg at 90 minutes (Do 2024).
One systematic review describes serotonin toxicity (a reaction from too much serotonin activity) from psilocybin as unlikely, because psilocybin causes minimal serotonin release (Sarparast 2022). Unlikely is not the same as impossible: the published data are small.
Psilodex presents published evidence and state psilocybin regulations for information only. It is not medical advice, a screening decision, or clearance to participate. Do not stop or change a medication without talking with the prescriber.
- Gukasyan N, Griffiths RR, Yaden DB, et al. Attenuation of psilocybin mushroom effects during and after SSRI/SNRI antidepressant use. J Psychopharmacol 2023;37:707–716.
- Do A, Michaud V, Stephan JF, et al. Serotoninergic antidepressants combination in psilocybin-assisted psychotherapy: a case report. Front Psychiatry 2024;15:1394962.
- Goodwin GM, Croal M, Feifel D, et al. Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication. Neuropsychopharmacology 2023;48(10):1492–1499.
- Becker AM, Holze F, Grandinetti T, et al. Acute effects of psilocybin after escitalopram or placebo pretreatment. Clin Pharmacol Ther 2022;111(4):886–895.
- Sarparast A, Thomas K, Malcolm B, Stauffer CS. Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review. Psychopharmacology 2022;239(6):1945–1976.
- Effexor XR (venlafaxine) prescribing information (DailyMed)
Also searched as SNRI · SNRIs
01 What the evidence covers
Best evidence available per medication| 1 | Case reports Case reports or online surveys |
| 2 | Other psychedelic Human data with another classic psychedelic (e.g. LSD), not psilocybin; named in the text |
| 2 | No psilocybin data No psilocybin data: no human data with psilocybin or another classic psychedelic; the text draws on the medication's own pharmacology and its label or reference facts |
02 Each medication
A to ZMajor depressive disorder (depression) in adults
It is expected to weaken psilocybin and may add to its blood pressure rise; serotonin syndrome is considered unlikely, though not impossible.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Depression (major depressive disorder); Generalized anxiety disorder
In one case, psilocybin with duloxetine was well tolerated except mild headache; blood pressure rose. Stopping it suddenly after regular use can cause withdrawal.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Major depressive disorder (MDD) in adults
It is expected to make psilocybin feel weaker, as SNRIs did in a survey; its heart rate and blood pressure rise may add to psilocybin's.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Fibromyalgia
In a survey, people on related drugs reported weaker psilocybin effects, so it is expected to weaken psilocybin and may add to its heart-rate rise.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Depression (major depressive disorder); Generalized anxiety disorder (GAD; extended-release)
It is expected to make psilocybin feel weaker, as SSRIs do, and higher doses may add to psilocybin's blood pressure rise.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
03 Properties the records flag
Records with each flag| 5 | Dehydration or electrolyte risk |
| 5 | Lowers seizure threshold or carries seizure risk |
| 5 | Psychiatric reactions |
| 5 | Raises blood pressure or heart rate |
| 5 | Serotonergic |
| 5 | Withdrawal or rebound if stopped abruptly |
| 2 | Lowers blood pressure or causes orthostasis |
| 1 | Liver injury |
Flags describe a medication's own properties, each cited in its record. A flag is not a finding about any combination. Definitions are on the Method page.
04 State rules
Official text governsNo provision names these medications or this group.
Rule 2.2(A)(9): a facilitator must tell prospective participants in writing that anyone taking a psychotropic medication identified as a risk factor on the safety screen must meet one of the 2.2(A)(7) conditions. Every medication in this group is psychotropic; the rule applies when one is identified as a risk factor on a participant's screen.
No provision names these medications or this group.
Rules not final; the proposed rules reviewed name no medication in this group.
05 Studies cited in this group
Records citing eachRelated classes
- Antidepressants5 shared
Records reviewed 2026-10-14. Each row summarizes one record; the full record, with every source, opens in the browser and is not sent to the server. All classes · Browse A–Z